Dog rose (Rosa canina L.) is a cosmopolitan plant species that due to its nutritional, medical and cosmetic values deserves more attention. Dog roses are cultivated in Croatia on very small scale and most of the rose hip used in the domestic processing industry is imported. In this study, three dog rose F1 progeny populations developed from selected plants collected in Korcula, Malesnica and Prigorje Brdovecko, originating from two climatic regions (P1 - Mediterranean and P2 and P3 - continental) have been studied as a part of a field experiment for two growing seasons, in order to assess the level of genetic variability for pomological and agronomic traits. In addition, genetic variation within and among examined three dog rose populations has been assessed using 6 polymorphic SSR markers. The highest variability, as well as the most desirable agronomic traits were found within the P3 population, while the lowest ones were present in the P1 population. Most desirable properties and highest values for commercially important traits were detected in the genotype RC29 (P3). Molecular data was sufficient to separate three studied populations but not all individuals within the populations. Through selection and hybridization of perspective genotypes of dog roses from Croatia, it would be possible to create clonally propagated varieties suitable for commercial cultivation.

We propose a procedure to cross-validate Monte Carlo implementations of the standard model effective field theory. It is based on the numerical comparison of squared amplitudes computed at specific phase-space and parameter points in pairs of implementations. Interactions are fully linearised in the effective field theory expansion. The squares of linear effective field theory amplitudes and their interference with standard-model contributions are compared separately. Such pairwise comparisons are primarily performed at tree level and a possible extension to the one-loop level is also briefly considered. We list the current standard model effective field theory implementations and the comparisons performed to date.

Zooropa better by designZooropa fly the friendly skiesThrough appliance of scienceWe’ve got that ring of confidenceAnd I have no compassAnd I have no mapAnd I have no reasonsNo reasons to get back—...

Recently a framework was presented to assess whether pediatric covariate models for clearance can be extrapolated between drugs sharing elimination pathways, based on extraction ratio, protein binding, and other drug properties. Here we evaluate when a pediatric covariate function for midazolam clearance can be used to scale clearance of other CYP3A substrates. A population PK model including a covariate function for clearance was developed for midazolam in children aged 1–17 years. Commonly used CYP3A substrates were selected and using the framework, it was assessed whether the midazolam covariate function accurately scales their clearance. For eight substrates, reported pediatric clearance values were compared numerically and graphically with clearance values scaled using the midazolam covariate function. For sildenafil, clearance values obtained with population PK modeling based on pediatric concentration-time data were compared with those scaled with the midazolam covariate function. According to the framework, a midazolam covariate function will lead to systemically accurate clearance scaling (absolute prediction error (PE) < 30%) for CYP3A substrates binding to albumin with an extraction ratio between 0.35 and 0.65 when binding < 10% in adults, between 0.05 and 0.55 when binding > 90%, and with an extraction ratio ranging between these values when binding between 10 and 90%. Scaled clearance values for eight commonly used CYP3A substrates were reasonably accurate (PE < 50%). Scaling of sildenafil clearance was accurate (PE < 30%). We defined for which CYP3A substrates a pediatric covariate function for midazolam clearance can accurately scale plasma clearance in children. This scaling approach may be useful for CYP3A substrates with scarce or no available pediatric PK information.